Moneycontrol PRO
HomeNewscoronavirusBharat Biotech's nasal COVID-19 vaccine to be available from today. Here's how you can get it

Bharat Biotech's nasal COVID-19 vaccine to be available from today. Here's how you can get it

The COVID-19 vaccine will now be offered to the adults earlier fully vaccinated with Covaxin or Covishield after the government incorporated changes in the CoWin app.

December 23, 2022 / 15:03 IST

The Union health ministry has decided to incorporate changes in the  CoWIN app to allow  addition of Bharat Biotech's nasal COVID-19 vaccine, paving way for its inclusion as a heterologous booster dose in the country's immunisation drive against coronavirus.

The option of this vaccine is set to reflect on CoWin to all users from the December 23 evening. This vaccine will now be offered to the adults earlier fully vaccinated with Covaxin or Covishield or to those who may not have taken any coronavirus vaccine so far.

It will, however, will only be available at private hospitals and the rate is yet to be determined. Government sources said that as of now there is no plan to procure the vaccine for the public run hospitals where booster or precautionary doses are offered free of cost to all those aged 60 years and above.

Also Read: Exclusive: States make desperate demands for more COVID-19 vaccines, Centre faces a stockout

Bharat Biotech, so far, has not released any official statement on the development but the company sources said that it may take several weeks before the vaccine hits the market. "It may take nearly 90 days before the sufficient stocks are available in the market," said an executive in the vaccine maker.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

There is no peer reviewed scientific data available publicly  on the efficacy of the vaccine but Bharat Biotech has said the nasal drop is capable of preventing transmission of COVID-19 disease too and not just disease severity unlike other vaccines against coronavirus.

The Drug Controller General of India had granted emergency use authorisation to the nasal vaccine for both homologous primary vaccination and heterologous booster vaccination recently.

The rise of mutant variants in the neighbouring nation may cause a fresh surge of infections in India, which is a cause of concern for the government especially amid its low stock of booster shots.

Three cases of Omicron subvariant BF.7, have been detected in India so far. The first case of BF.7 in India was detected July this year by Gujarat Biotechnology Research Centre. So far, two cases have been reported from Gujarat while one case has been reported from Odisha.

India has seen three waves of the pandemic so far, with the second one, triggered by the Delta variant of SARS CoV 2, turning out to be the worst.

Sumi Sukanya Dutta
Sumi Sukanya Dutta
first published: Dec 23, 2022 11:35 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347